Metabolomic and multi-omic predictors of inhaled corticosteroid response in obese and non-obese asthma

Active Grant Awarded

Award ID
K08HL183790
Recipient
Awarding agency
Obligated
$163,414

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 4% complete
Place of performance
Aurora, CO 80045, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $163,414 on September 9, 2026, under Assistance Listing 93.837, Cardiovascular Diseases Research. The award obligates funds to a project that identifies metabolite profiles predicting inhaled corticosteroid (ICS) response in a high-risk, understudied asthma population, including obese and non-obese patients. The project pursues three specific aims: identifying metabolite profiles associated with ICS response; integrating genetic and metabolomic data to identify metabolite quantitative trait loci that reveal the genetic basis of those metabolites; and developing a machine learning metabolite prediction model for ICS response in a diverse asthma population. The work draws on metabolomic, oxylipin, and genetic data from the Best African American Response to Asthma Drugs (BARD) clinical trial. Place of performance is Aurora, Colorado 80045. The ultimate completion date is May 31, 2031.

Description

Abstract
Inhaled corticosteroids (ICS) are the backbone of asthma therapy, however as many as 35% of patients do not have adequate treatment response to ICS. Poor ICS response is most prevalent in high-risk groups including non-white populations and those with obesity. These groups also experience the highest morbidity and exacerbation rates among those with asthma. Because mechanisms driving treatment response are unknown, we cannot prospectively develop optimal treatment regimens for patients. Understanding metabolomic differences in treatment response is a powerful tool to disentangle complex genetic and environmental processes in populations that are disproportionately affected by treatment non-response and increased asthma burden. The goal of this project is to identify metabolite profiles that predict ICS response and understand genetic contributions of these metabolic traits in a high-risk, understudied asthma population. I hypothesize that there will be distinct metabolite profiles that include arginine, oxylipin, and other oxidative stress pathways associated with ICS response and that ICS response in patients with increasing BMI will be associated with proline and polyamines, and that these metabolites will colocalize with known loci associated with ICS response. This project will be accomplished in three specific aims: specific aim 1: identify metabolite profiles associated with ICS response. Specific aim 2: integrate genetic and metabolomic data to identify metabolite quantitative trait loci (MTQTL) to understand the genetic basis of metabolites associated with ICS response. Specific aim 3: develop a metabolite prediction model for ICS response using machine learning approaches in a diverse asthma population. I will use metabolomic, oxylipin, and genetic data from the best african american response to asthma drugs (BARD) clinical trial, a four-way randomized crossover trial in adults and children with asthma and self-identified black race. I will perform targeted metabolomic analysis of arginine metabolites and oxylipins and untargeted metabolomics serum to identify pathways associated with ICS response. Using existing genetic data, I will identify mtqtls to understand the genetic contribution to novel and pre-specified metabolites associated with ICS treatment response. I will examine how obesity modifies these metabolite profiles and mtqtls to identify mechanisms in this high-risk group. Finally, I will quantify novel and pre-specified metabolites in the BARD cohort and two additional asthma clinical trials, siena and stics. I will use machine learning approaches to develop a prediction model for ICS response using metabolites and clinical data with stratification by cohort to evaluate for heterogeneity of prediction model by cohort composition. The anticipated outcomes of this project are (1) to gain a deeper understanding of the metabolic pathways and genetic factors that affect ICS response, and (2) to complete a rigorous career development plan that provides advanced training in metabolomics, integrative omics, and machine learning, equipping me to become an independent investigator in asthma treatment response and personalized medicine.

Quick answers

Who received award K08HL183790?

K08HL183790 was awarded to The Regents Of The University Of Colorado by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.

How much is award K08HL183790 worth?

$163,414 has been obligated on K08HL183790.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award